Watson’s FDA approval for generic C. difficile treatment prompts complaint
Watson Pharmaceuticals (NYSE:WPI) received approval from the U.S. Food and Drug Administration for its generic version of a drug to treat C. difficile. Watson submitted an abbreviated new drug application for vancomycin hydrochloride capsules, USP, in 125 mg and 250 mg doses, used to treat diarrhea caused by C. difficile and for the treatment of […]